Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients.

Tofacitinib, a Janus kinase (JAK) inhibitor, is a promising agent for BS patients who have unsatisfactory responses to corticosteroids, traditional disease-modifying antirheumatic drugs, and biological agents.